ArticleOpen heart2026

Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system.

Jialing Qian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.